Got to News overview News

MR GENTLE trial completes patient enrollment

News Other

We are pleased to announce that patient enrollment in the MR GENTLE trial has been successfully completed. A total of 81 patients with acute ischemic stroke were included across four participating centers in the Netherlands.

The MR GENTLE trial is a phase 2 randomised, placebo-controlled trial investigating the potential neuroprotective effects of acyl-ghrelin in patients with acute ischaemic stroke undergoing endovascular thrombectomy (EVT). The trial aims to evaluate whether treatment with acyl-ghrelin can improve neurological recovery and reduce infarct volume after EVT.

We are grateful to all participating patients and their families. We would also like to take the opportunity to thank the local investigators, research nurses, and research teams at the participating centers for their contributions to the trial.

Assessment of the primary outcome, the National Institutes of Health Stroke Scale (NIHSS) score at day 7 or hospital discharge, has been completed for all patients. Follow-up is currently ongoing, with the final 90-day follow-up assessments expected to be completed in November 2026. Following completion of follow-up, we look forward to analysing and sharing the results of the MR GENTLE trial. 

More information on the MR GENTLE trial can be found here.

Share this page…